SCP
VRDN icon

Sender Company & Partners’s Viridian Therapeutics VRDN Stock Holding History

Sender Company & Partners’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-12,216
Closed -$242K – 105
2021
Q4 		$242K Buy
+12,216
New +$228K 0.12% 85

Other funds holding VRDN

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Sender Company & Partners's VRDN Position: Q1 2022 in Review

Sender Company & Partners sold out of Viridian Therapeutics (VRDN) in Q1 2022, closing a stake of 12,216 shares — an estimated $242K sold.

Sender Company & Partners first reported a position in VRDN in Q4 2021 and held it in 1 quarter. The position peaked at $242K in Q4 2021. 72 funds tracked by Wall St. Rank hold VRDN as of Q1 2022.

  • Sender Company & Partners reported no remaining Viridian Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Sender Company & Partners sold 12,216 Viridian Therapeutics shares in Q1 2022, an estimated $242K.
  • Sender Company & Partners first reported a position in Viridian Therapeutics in Q4 2021 and held it in 1 quarter.
  • Sender Company & Partners's Viridian Therapeutics position peaked at $242K in Q4 2021.
  • 72 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2022.

Based on Sender Company & Partners's 13F filing for Q1 2022, filed 17 May 2022.